Loading
PTPN6 (Tyrosine-protein phosphatase non-receptor type 6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Diffuse large B-cell lymphoma and Melanoma.
Tyrosine phosphatase enzyme that plays important roles in controlling immune signalling pathways and fundamental physiological processes such as haematopoiesis. Dephosphorylates and negatively regulate several receptor tyrosine kinases (RTKs) such as EGFR, PDGFR and FGFR, thereby modulating their signalling activities. When recruited to immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptors such as immunoglobulin-like transcript 2/LILRB1, programmed cell death protein 1/PDCD1, CD3D, CD22, CLEC12A and other receptors involved in immune regulation, initiates their dephosphorylation and subsequently inhibits downstream signalling events.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Melanoma.
In plain words · PTPN6 (Tyrosine-protein phosphatase non-receptor type 6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Diffuse large B-cell lymphoma and Melanoma.
PTPN6 (Tyrosine-protein phosphatase non-receptor type 6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Diffuse large B-cell lymphoma and Melanoma.
Tyrosine phosphatase enzyme that plays important roles in controlling immune signalling pathways and fundamental physiological processes such as haematopoiesis.
No product in this corpus aims at PTPN6 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA PTPN6: RNA tissue enhanced (bone marrow 125 nTPM, lymphoid tissue 144 nTPM); high antibody staining in 6 normal tissues; highest cancer staining lymphoma (12 of 12 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Hepatocellular carcinoma, Lymphoma, Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P29350; CIViC gene PTPN6; IntOGen PTPN6; Human Protein Atlas PTPN6 tissue; Open Targets ENSG00000111679 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Shen S.H. et al, Nature, 1991, "A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases". Source.
Sources: HGNC HGNC:9658 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P29350 (protein name, function text, keywords and locations (REST API)); CIViC gene PTPN6 (1 evidence items, 0 assertions, 1 variants; diseases: Hepatocellular Carcinoma (GraphQL API, CC0)); IntOGen PTPN6 (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Tyrosine phosphatase enzyme that plays important roles in controlling immune signalling pathways and fundamental physiological processes such as haematopoiesis. Dephosphorylates and negatively regulate several receptor tyrosine kinases (RTKs) such as EGFR, PDGFR and FGFR, thereby modulating their signalling activities. When recruited to immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptors such as immunoglobulin-like transcript 2/LILRB1, programmed cell death protein 1/PDCD1, CD3D, CD22, CLEC12A and other receptors involved in immune regulation, initiates their dephosphorylation and subsequently inhibits downstream signalling events. Modulates the signalling of several cytokine receptors including IL-4 receptor. Additionally, targets multiple cytoplasmic signalling molecules including STING1, LCK or STAT1 among others involved in diverse cellular processes including modulation of T-cell activation or cGAS-STING signalling. Within the nucleus, negatively regulates the activity of some transcription factors such as NFAT5 via direct dephosphorylation. Location: Cytoplasm; Nucleus (UniProt). Locus 12p13.31 (HGNC).
RNA: tissue enhanced (bone marrow 125 nTPM, lymphoid tissue 144 nTPM), detected in many normal tissues.
Medium: Testis.
Medium only: carcinoid, cervical cancer, colorectal cancer, head and neck cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PTPN6" OR ABSTRACT:"PTPN6" OR TITLE:"protein tyrosine phosphatase non-receptor type 6" OR ABSTRACT:"protein tyrosine phosphatase non-receptor type 6" OR TITLE:"Tyrosine-protein phosphatase non-receptor type 6" OR ABSTRACT:"Tyrosine-protein phosphatase non-receptor type 6" OR TITLE:"PTP-1C" OR ABSTRACT:"PTP-1C" OR TITLE:"SHP-1" OR ABSTRACT:"SHP-1" OR TITLE:"SHP1" OR ABSTRACT:"SHP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTPN6, not a curated reading list.